Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises on Harbour BioMed's US$220 million Hong Kong IPO and Listing

  • en
  • zh
  • Language options

10 December 2020

Clifford Chance advises on Harbour BioMed's US$220 million Hong Kong IPO and Listing

Leading international law firm Clifford Chance has advised the joint sponsors Morgan Stanley, Bank of America Securities, CLSA and joint global coordinators CICC and Credit Suisse on biopharmaceutical company Harbour BioMed's US$220 million IPO and listing on the main board of the Hong Kong Stock Exchange (SEHK). Shanghai-based Harbour BioMed engages in the discovery and development of novel antibody therapies in immunology and oncology.

Partner Fang Liu commented: "We continue to see great momentum in biotech company IPOs under the SEHK' ground-breaking Chapter 18A regime and look forward to working with more high quality issuers like Harbour BioMed."

Fang and partner Christine Xu co-led on the deal, with support from a team in Hong Kong, Beijing and Shanghai including senior associates Sheng Chen and Samson Chan, and associates Alex Feng, Jiawei Zhao, Dichun Duan and Jingxuan Liu.

Clifford Chance's market leading Greater China IPO practice continues to advise on the equity fundraising of the most innovative biotech and healthcare companies, including Hygeia Healthcare, Genetron and Ascentage Pharma.